NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $8.23 -0.24 (-2.83%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.09▼$8.5950-Day Range$8.23▼$12.4952-Week Range$5.05▼$14.99Volume11,638 shsAverage Volume85,170 shsMarket Capitalization$428.19 millionP/E RatioN/ADividend YieldN/APrice Target$36.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GH Research alerts: Email Address GH Research MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside345.5% Upside$36.67 Price TargetShort InterestBearish4.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.84) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 starsMedical Sector697th out of 910 stocksPharmaceutical Preparations Industry327th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 2 research reports in the past 90 days.Read more about GH Research's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.80% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 33.1, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 1.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GHRS. Previous Next 2.0 News and Social Media Coverage News SentimentGH Research has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for GH Research this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.84) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -13.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -13.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About GH Research Stock (NASDAQ:GHRS)GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More GHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GHRS Stock News HeadlinesSeptember 6 at 5:25 AM | americanbankingnews.comGH Research (NASDAQ:GHRS) Receives Buy Rating from HC WainwrightSeptember 5 at 2:12 PM | markets.businessinsider.comBuy Rating Affirmed on GH Research Amid Anticipated Phase 2 Advances and Strong Market PotentialSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 5 at 2:12 PM | msn.comIrish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug TrialsSeptember 5 at 9:12 AM | markets.businessinsider.comMaintaining Buy Rating on GH Research Amidst CEO Transition and Promising GH001 TrialsSeptember 5 at 3:55 AM | americanbankingnews.comGH Research (NASDAQ:GHRS) Receives Market Outperform Rating from JMP SecuritiesSeptember 4 at 4:40 PM | markets.businessinsider.comBuy Rating Affirmed for GH Research Amid Anticipated Clinical Advances and Strong LeadershipSeptember 3, 2024 | nasdaq.comGH Research Names Velichka Villy Valcheva CEO - Quick FactsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 3, 2024 | globenewswire.comGH Research Reports Second Quarter 2024 Financial Results and Provides Business UpdatesSeptember 3, 2024 | globenewswire.comGH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive OfficerSeptember 2, 2024 | americanbankingnews.comComparing Gemini Therapeutics (NASDAQ:GMTX) & GH Research (NASDAQ:GHRS)August 29, 2024 | americanbankingnews.comGH Research (NASDAQ:GHRS) Shares Gap Down to $11.04August 24, 2024 | uk.finance.yahoo.comGH Research PLC (1KA.F)August 22, 2024 | uk.finance.yahoo.comGH Research PLC (1KA.SG)July 19, 2024 | seekingalpha.comGHRS GH Research PLCJuly 6, 2024 | investorplace.com3 Psychedelic Stocks to Ride to the Moon and BeyondMay 10, 2024 | finance.yahoo.comWall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should KnowSee More Headlines Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/03/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$40.00 Low Stock Price Target$31.00 Potential Upside/Downside+345.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-14.56% Return on Assets-14.10% Debt Debt-to-Equity RatioN/A Current Ratio22.06 Quick Ratio22.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book1.67Miscellaneous Outstanding Shares52,028,000Free Float30,384,000Market Cap$428.19 million OptionableOptionable Beta0.83 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Florian Schonharting M.Sc. (Econ) (Age 55)Co-Founder & Non-Executive Chairman of the Board Dr. Theis Terwey M.D. (Age 48)Co-Founder & CEO Mr. Magnus Halle (Age 27)Co-Founder & MD of Ireland Ms. Julie Ryan F.C.A. (Age 38)Vice President of Finance Mr. Aaron Cameron M.B.A. (Age 39)Chief Operating Officer Mr. Naoise GaffneyVP & Head of Intellectual PropertyDr. Velichka Valcheva M.D. (Age 49)Chief Medical Officer More ExecutivesKey CompetitorsDesign TherapeuticsNASDAQ:DSGNAtai Life SciencesNASDAQ:ATAIRevance TherapeuticsNASDAQ:RVNCSangamo TherapeuticsNASDAQ:SGMOPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInstitutional OwnershipLynx1 Capital Management LPBought 656,163 shares on 8/15/2024Ownership: 7.624%AdvisorShares Investments LLCSold 7,458 shares on 8/8/2024Ownership: 0.043%View All Institutional Transactions GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $5.80 at the beginning of the year. Since then, GHRS shares have increased by 41.9% and is now trading at $8.23. View the best growth stocks for 2024 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) issued its quarterly earnings data on Tuesday, September, 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are GH Research's major shareholders? Top institutional shareholders of GH Research include Lynx1 Capital Management LP (7.62%) and AdvisorShares Investments LLC (0.04%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GHRS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
